Neuroprotective Effect of the Neuropeptide Cycloprolylglycine Depends on AMPA- and TrkB-Receptor Activation.
Gudasheva TA, Koliasnikova KN, Alyaeva AG, Nikolaev SV, Antipova TA, Seredenin SB · 2022 · Doklady. Biochemistry and biophysics
What does this source report?
AMPA and Trk receptor blockers prevented the reported CPG neuroprotective effect in cultured-cell experiments. Pharmacological blockade supports pathway involvement, not a fully resolved mechanism.
- Population and setting
- Cultured-cell injury and receptor-blockade experiments
- Evidence type
- In vitro
- Preparation
- See the original report; formulation details require verification.
- Source language
- English indexed abstract; original language: eng
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Preclinical findings do not establish human benefit or safety.
- Indexed abstract reviewed; full methods and independent replication require appraisal.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Abstract reviewed
Source access and review scope
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Recorded source-check date: 2026-10-05. This date does not imply a completed systematic review.
Cite and trace this record
Original source: Gudasheva TA, Koliasnikova KN, Alyaeva AG, Nikolaev SV, Antipova TA, Seredenin SB. Neuroprotective Effect of the Neuropeptide Cycloprolylglycine Depends on AMPA- and TrkB-Receptor Activation. Doklady. Biochemistry and biophysics 2022.
Molekul research summary: https://molekul.io/research/rp-36786983. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry